If you or a loved one takes Tysabri, understanding the warning signs of progressive multifocal leukoencephalopathy (PML) is critical. Recent studies have identified specific clinical red flags that can help with early detection. Building on decades of pharmaceutical safety research, this page outlines what these red flags mean and how they guide monitoring strategies.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Ohio who have developed PML after Tysabri exposure, understanding the medical evidence and legal considerations, including the statute of limitations for filing a claim, is critical. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing surveillance. The prescribing information identifies three key risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, as the expected benefit must be weighed against the PML risk.
PML typically presents with subacute neurological deficits, including cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. The clinical course is often devastating, with most patients experiencing severe disability or death. The mechanistic link between Tysabri and PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect impairs immune surveillance against JC virus, allowing reactivation and lytic infection of oligodendrocytes. The adequacy of warnings regarding Tysabri and PML has been a subject of litigation. The FDA-approved labeling includes a boxed warning and mandates enrollment in the TOUCH Prescribing Program, which requires patients to read a Medication Guide and acknowledge risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, plaintiffs have argued that these warnings were insufficient to fully inform patients and healthcare providers about the magnitude of PML risk, particularly in the context of long-term therapy.
Settlement considerations for affected patients often involve evaluating the timing of diagnosis, the presence of risk factors, and whether the patient received adequate monitoring. The FDA advises that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Delays in diagnosis or failure to discontinue therapy upon symptom onset may be relevant to claims. For Ohio residents, the statute of limitations for product liability claims, including those related to Tysabri and PML, is generally two years from the date the injury was discovered or reasonably should have been discovered. This timeline is critical because PML often has a latency period of months to years after Tysabri initiation. The prescribing information notes that "longer treatment duration, especially beyond 2 years" increases PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Therefore, the date of harm may be tied to the onset of neurological symptoms, which can be gradual. Patients and their families should document the timeline of Tysabri exposure, symptom onset, and PML diagnosis to preserve legal options.
In summary, Tysabri-associated PML is a severe adverse event with established risk factors and a clear mechanistic basis. The FDA's boxed warning and TOUCH program aim to mitigate risk, but settlements have been pursued by affected patients. In Ohio, the two-year statute of limitations from discovery of injury applies, making prompt legal consultation essential for those diagnosed with PML after Tysabri use. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Ohio, the statute of limitations for product liability claims related to Tysabri and PML is generally two years from the date the injury was discovered or reasonably should have been discovered. This timeline is critical because PML symptoms may develop gradually, and the clock starts ticking once the patient knows or should know of the link between Tysabri and their injury.
The prescribing information identifies three key risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be considered when initiating or continuing therapy, as the expected benefit must be weighed against the PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
If you experience symptoms such as cognitive decline, motor weakness, visual disturbances, or speech difficulties while on Tysabri, seek immediate medical evaluation. The FDA advises that Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Prompt diagnosis and legal consultation are essential.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.